New agents for thromboprotection

L. Labberton; E. Kenne; T. Renné

doi:10.5482/HAMO-14-11-0060

Hämostaseologie, Table of Contents

Hamostaseologie 2015; 35(04): 338-350
DOI: 10.5482/HAMO-14-11-0060

Review

Schattauer GmbH

New agents for thromboprotection

A role for factor XII and XIIa inhibitionNeue Strategien zur sicheren AntikoagulanzInhibition von Faktor XII und Faktor XIIa

L. Labberton

¹Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm

²Center of Molecular Medicine, Karolinska Institutet, Stockholm

,

E. Kenne

¹Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm

²Center of Molecular Medicine, Karolinska Institutet, Stockholm

,

T. Renné

¹Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm

²Center of Molecular Medicine, Karolinska Institutet, Stockholm

³Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Germany

› Author Affiliations

Abstract

Summary

Blood coagulation is essential for hemostasis, however excessive coagulation can lead to thrombosis. Factor XII starts the intrinsic coagulation pathway and contact-induced factor XII activation provides the mechanistic basis for the diagnostic aPTT clotting assay. Despite its function for fibrin formation in test tubes, patients and animals lacking factor XII have a completely normal hemostasis. The lack of a bleeding tendency observed in factor XII deficiency states is in sharp contrast to deficiencies of other components of the coagulation cascade and factor XII has been considered to have no function for coagulation in vivo. Recently, experimental animal models showed that factor XII is activated by an inorganic polymer, polyphosphate, which is released from procoagulant platelets and that polyphosphate-driven factor XII activation has an essential role in pathologic thrombus formation. Cumulatively, the data suggest to target polyphosphate, factor XII, or its activated form factor XIIa for anticoagulation. As the factor XII pathway specifically contributes to thrombosis but not to hemostasis, interference with this pathway provides a unique opportunity for safe anticoagulation that is not associated with excess bleeding.

The review summarizes current knowledge on factor XII functions, activators and inhibitors.

Zusammenfassung

Die Blutgerinnung ist notwendig zur Blutstillung bei Verletzungen, kann aber auch zu Thrombosen führen. Faktor XII startet die intrinsische Blutgerinnungskaskade und dieser Mechanismus ist die Basis für den millionenfach eingesetzten aPTT-Gerinnungstest. Trotz seiner Bedeutung für die Fibrinbildung im Reagenzglas ist ein Mangel an Faktor XII we-der bei Mensch noch Tier mit einer erhöhten pathologischen Blutungsneigung assoziiert. Daher dachte man über Jahrzehnte, dass Faktor XII keine Funktion für die Blutgerinnung in vivo habe. In den vergangenen Jahren haben experimentelle Tiermodelle gezeigt, dass Faktor XII durch das anorganische Polymer Polyphosphat auf prokoagulanten Thrombozyten aktiviert wird. Die Polyphosphat-getriebene Faktor-XII-vermittelte Fibrinbildung hat eine essenzielle Funktion für die Bildung von Thromben, aber keine Funktion für hämostatische Mechanismen. Daher sind Polyphosphat, Faktor-XII-Zymogen und die aktive Protease attraktive Zielstrukturen für sichere Antikoagulanzien, die im Gegensatz zu aktuellen Medikamenten nicht mit Blutungsnei-gung assoziiert sind.

Diese Übersichtsarbeit fasst das aktuelle Wissen über Faktor XII, seinen Aktivator Polyphosphat und Inhibitoren dieser beiden Substanzen zusammen.

Keywords

Factor XII - contact system - anticoagulants - polyphosphate

Schlüsselwörter

Faktor XII - Kontaktphasesystem - Antikoagulanz - Polyphosphat

Full Text

References

References
1 Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
2 Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 2001; 500: 36-40.
3 Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-33696.
4 Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/ kinin system: a new interpretation. Int Immunopharmacol 2002; 02: 1841-1849.
5 Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125: 210-215.
6 Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-381.
7 LaRusch GA, Mahdi F, Shariat-Madar Z. et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis Blood. 2010; 115: 5111-5120.
8 Doolittle RF. Coagulation in vertebrates with a focus on evolution and inflammation. J Innate Immun 2011; 03: 9-16.
9 Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 06: 1876-1883.
10 Maas C, Renne T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012; 129 (Suppl. 02) S73-S76.
11 Kenne E, Renne T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discovery Today 2014; 19: 1459-1464.
12 Palmer RN, Gralnick HR. Cold-induced contact surface activation of the prothrombin time in whole blood. Blood 1982; 59: 38-42.
13 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50-68.
14 Konings J, Govers-Riemslag JW, Philippou H. et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-3951.
15 Bjorkqvist J, Nickel KF, Stavrou E, Renne T. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014; 112: 868-875.
16 Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-1010.
17 Coffman LG, Brown JC, Johnson DA. et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 2008; 294: L505-L515.
18 Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900.
19 Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 2005; 289: H2697-H2703.
20 Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
21 Lindsay SL, Ramsey S, Aitchison M. et al. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J Cell Sci 2007; 120: 3011-3021.
22 Benz PM, Blume C, Moebius J. et al. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alpha II-spectrin-VASP complexes. J Cell Biol 2008; 180: 205-219.
23 Anton KA, Sinclair J, Ohoka A. et al. PKA-regulated VASP phosphorylation promotes extrusion of transformed cells from the epithelium. J Cell Sci 2014; 127: 3425-3433.
24 Tiruppathi C, Ahmmed GU, Vogel SM, Malik AB. Ca2+ signaling, TRP channels, and endothelial permeability. Microcirculation 2006; 13: 693-708.
25 Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-3385.
26 Paegelow I, Trzeczak S, Bockmann S, Vietinghoff G. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 2002; 66: 153-161.
27 Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-374.
28 Cichon S, Martin L, Hennies HC. et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
29 Orfeo T, Brummel-Ziedins KE, Gissel M. et al. The nature of the stable blood clot procoagulant activities. J Biol Chem 2008; 283: 9776-9786.
30 Bos MH, Camire RM. Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation. J Coagul Disord 2010; 02: 19-27.
31 Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-2513.
32 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613.
33 Kumar R, Carcao M. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am 2013; 60: 1419-1441.
34 Pauer HU, Renne T, Hemmerlein B. et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-508.
35 Renne T, Pozgajova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
36 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
37 Girolami A, Allemand E, Bertozzi I. et al. Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol 2010; 123: 210-214.
38 Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.
39 Renne T, Oschatz C, Seifert S, Muller F, Antovic J, Karlman M. et al. Factor XI deficiency in animal models. J Thromb Haemost 2009; 07 (Suppl. 01) 79-83.
40 Kravtsov DV, Matafonov A, Tucker EI. et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-458.
41 Mitropoulos KA. High affinity binding of factor XIIa to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro. Thromb Res 1999; 94: 117-129.
42 Vogler EA, Graper JC, Harper GR. et al. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res 1995; 29: 1005-1016.
43 Mutch NJ, Waters EK, Morrissey JH. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. J Thromb Haemost 2012; 10: 2108-2115.
44 Jordan SW, Chaikof EL. Novel thromboresistant materials. J Vasc Surg 2007; 45 (Suppl A): A104-A115.
45 Frank RD, Mueller U, Lanzmich R, Floege J. Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride. J Mater Sci Mater Med 2013; 24: 2561-25676.
46 Svensson M, Friberger P, Lundstrom O, Stegmayr B. Activation of FXII during haemodialysis. Scand J Clin Lab Invest 1996; 56: 649-652.
47 Cugno M, Nussberger J, Biglioli P. et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-1782.
48 Bjorkqvist J, Lecher B, Maas C, Renne T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem 2013; 394: 1195-1204.
49 Siebeck M, Cheronis JC, Fink E. et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994; 77: 2675-2680.
50 Renne T, Schmaier AH, Nickel KF. et al. In vivo roles of factor XII. Blood 2012; 120: 4296-4303.
51 Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009; 01: 225-230.
52 Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130 (Suppl. 01) S78-S83.
53 White-Adams TC, Berny MA, Patel IA. et al. Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost 2010; 08: 1295-1301.
54 Van der Meijden PEJ, Munnix ICA, Auger JM. et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114: 881-890.
55 Kuijpers MJE, van der Meijden PEJ, Feijge MAH. et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34: 1674-1680.
56 Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R. et al. Plateletand erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
57 Brunnee T, Reddigari SR, Shibayama Y. et al. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 1997; 27: 653-663.
58 Oschatz C, Maas C, Lecher B. et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268.
59 Sala-Cunill A, Bjorkqvist J, Senter R. et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol. 2014 doi: 10.1016/j.jaci.2014.07.057.
60 Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin Thromb Hemost 1997; 23: 3-10.
61 Blossom DB, Kallen AJ, Patel PR. et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674-2684.
62 Guerrini M, Beccati D, Shriver Z. et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675.
63 Rojkjaer R, Schousboe I. The surface-dependent autoactivation mechanism of factor XII. Eur J Biochem 1997; 243: 160-166.
64 Maas C, Govers-Riemslag JW, Bouma B. et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-3218.
65 Kannemeier C, Shibamiya A, Nakazawa F. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
66 Pavlov V, Zorn M, Kramer R. Probing singlestranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade. Biochem Biophys Res Commun 2006; 349: 1011-1015.
67 Von Bruhl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
68 Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978; 75: 1998-2002.
69 Johne J, Blume C, Benz PM. et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-178.
70 Back J, Sanchez J, Elgue G. et al. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 2010; 391: 11-17.
71 Johne J, Blume C, Benz PM. et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-178.
72 Muller F, Renne T. Platelet polyphosphates: the nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 2011; 71: 82-86.
73 Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-44257.
74 Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int J Hematol 2012; 95: 346-352.
75 Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem 2012; 287: 28435-28444.
76 Lorenz B, Leuck J, Kohl D. et al. Anti-HIV-1 activity of inorganic polyphosphates. J Acqui Immune Defic Syndr Hum Retroviro 1997; 14: 110-118.
77 Muller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
78 Cowling RT, Birnboim HC. Incorporation of [P-32] orthophosphate into inorganic polyphosphates by human granulocytes and other human cell-types. J Biol Chem 1994; 269: 9480-9485.
79 Kulakovskaya TV, Vagabov VM, Kulaev IS. Inorganic polyphosphate in industry, agriculture and medicine: Modern state and outlook. Process Biochem 2012; 47: 1-10.
80 Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: A molecule of many functions. Ann Rev Biochem 1999; 68: 89-125.
81 Smith SA, Mutch NJ, Baskar D. et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
82 Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 06: 1750-1756.
83 Montilla M, Hernandez-Ruiz L, Garcia-Cozar FJ. et al. Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with glycoprotein Ib. J Thromb Haemost 2012; 10: 2315-2323.
84 Gahl WA, Brantly M, Kaiser-Kupfer MI. et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998; 338: 1258-1264.
85 Hernandez-Ruiz L, Saez-Benito A, Pujol-Moix N. et al. Platelet inorganic polyphosphate decreases in patients with delta storage pool disease. J Thromb Haemost 2009; 07: 361-363.
86 Ghosh S, Shukla D, Suman K, Lakshmi BJ. et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122: 1478-1486.
87 Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
88 Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. Thromb Haemost. 2014 113. http://dx.doi.org/10.1160/TH14–06–0515.
89 Smith SA, Choi SH, Davis-Harrison R. et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
90 Mutch NJ, Engel R, Uitte Sde Willige. et al. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-3988.
91 Nickel KF, Spronk HM, Mutch NJ, Renne T. Timedependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-3849.
92 Morrissey JH, Smith SA. Comment on Faxalv et al. “Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII”. Blood. 2013 122. http://dx.doi.org/ 10.1182/blood-2013–05–499384
93 Travers RJ, Shenoi RA, Kalathottukaren MT. et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124: 3183-3190.
94 Matafonov A, Leung PY, Gailani AE. et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-1746.
95 Revenko AS, Gao DC, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
96 Yau JW, Liao P, Fredenburgh JC. et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014; 123: 2102-2107.
97 Yau JW, Stafford AR, Liao P. et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomaterial 2012; 08: 4092-4100.
98 Campos IT, Tanaka-Azevedo AM, Tanaka AS. Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett 2004; 577: 512-516.
99 Hagedorn I, Schmidbauer S, Pleines I. et al. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
100 Chen JW, Figueiredo JL, Wojtkiewicz GR. et al. Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging 2012; 05: 1127-1138.
101 Xu Y, Cai TQ, Castriota G. et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111: 694-704.
102 Larsson M, Rayzman V, Nolte MW. et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 06: 222ra17.
103 Bhandari R, Juluri KR, Resnick AC, Snyder SH. Gene deletion of inositol hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin secretion, growth, and spermiogenesis. Proc Natl Acad Sci USA 2008; 105: 2349-2353.
104 Alvarenga PH, Xu XQ, Oliveira F. et al. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol 2013; 33: 2759-2770.
105 Jain S, Pitoc GA, Holl EK. et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA 2012; 109: 12938-12943.
106 Smith SA, Choi SH, Collins JNR. et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
107 Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let’s meet the challenge. Int J Pharm 2010; 394: 122-142.
108 Jones CF, Campbell RA, Brooks AE. et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS nano 2012; 06: 9900-9910.
109 Saito H, Ishihara T, Suzuki H, Watanabe T. Production and characterization of a murine monoclonal-antibody against a hevay-chain of Hageman factor (factor XII). Blood 1985; 65: 1263-1268.
110 Small EJ, Katzmann JA, Tracy RP. et al. A monoclonal-antibody that inhibits activation of human Hageman-factor (factor XII). Blood 1985; 65: 202-210.
111 Pixley RA, Stumpo LG, Birkmeyer K. et al. A monoclonal-antibody recognizing an icosapeptide sequence in the heavy-chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262: 10140-10145.
112 Pixley RA, De La Cadena R, Page JD. et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-68.
113 Jansen PM, Pixley RA, Brouwer M. et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-2344.
114 Isawa H, Yuda M, Orito Y, Chinzei Y. A mosquito salivary protein inhibits activation of the plasma contact system by binding to factor XII and high molecular weight kininogen. J Biol Chem 2002; 277: 27651-27658.
115 Ishimaru Y, Gomez EA, Zhang FF. et al. Dimiconin, a novel coagulation inhibitor from the kissing bug, Triatoma dimidiata, a vector of Chagas disease. J Exp Biol 2012; 215: 3597-3602.
116 Baeriswyl V, Calzavarini S, Gerschheimer C. et al. Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy. J Med Chem 2013; 56: 3742-3746.
117 Woodruff RS, Xu Y, Layzer J. et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost 2013; 11: 1364-1373.
118 Esnouf MP, Burgess AI, Dodds AW. et al. A monoclonal antibody raised against human betafactor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C(1)over-bar esterase inhibitor. Thromb Haemost 2000; 83: 874-881.
119 Hojima Y, Pierce JV, Pisano JJ. Hageman-factor fragment inhibitor in corn seeds – purification and characterization. Thromb Res 1980; 20: 149-162.
120 Ulmer JS, Lindquist RN, Dennis MS, Lazarus RA. Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein. FEBS Lett 1995; 365: 159-163.
121 Caliezi C, Wuillemin WA, Zeerleder S. et al. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112.
122 Rajapakse N, Jung WK, Mendis E. et al. A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation. Life Sci 2005; 76: 2607-2619.
123 Robert S, Bertolla C, Masereel B. et al. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem 2008; 51: 3077-3080.
124 Decrem Y, Rath G, Blasioli V. et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009; 206: 2381-2395.